Project Grant R15AI203617
Award Date 9/1/26
Completion Date 8/31/29
Dollars Obligated $570K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Johnson City, TN 37614, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Tennessee $230,313 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a genome-wide CRISPR screening platform in diploid Candida albicans for identifying mechanisms of antifungal resistance. The project will create tools for efficient DNA transformation and CRISPR-based genome editing in C. albicans, then apply these tools to perform genome-wide screening to...
- The National Institute of Allergy and Infectious Diseases awarded East Tennessee State University $570,000 on August 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of the KEAP1-NRF2 pathway in Epstein-Barr virus pathogenesis. The research examines how EBV exploits the master antioxidant KEAP1-NRF2 signaling pathway beyond its classical antioxidant function to promote viral persistence. The project will determine how NRF2 activation...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pennsylvania $446,875 on July 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to advance acceptability and ethical readiness for innovative HIV cell and gene therapies in the United States. The award funds research examining how people living with HIV perceive the risks, benefits, and acceptability of cell and gene therapy (CGT)–based interventions, including CAR-T cells,...
- The National Institute of Allergy and Infectious Diseases awarded Case Western Reserve University $816,379 on May 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop HIV-CRISP, a point-of-care device for same-visit HIV viral load and drug resistance testing. The project delivers a fully automated, CRISPR-based nucleic acid detection platform integrated with a bioinspired microfluidic chip (CAMOCHIP) that simultaneously detects HIV viral load and...
- The National Institute of Allergy and Infectious Diseases awarded East Tennessee State University $142,785 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize neutrophil swarming responses to fungal pathogens relevant to diabetes mellitus. The research addresses invasive fungal infections caused by Candida, Aspergillus, and Zygomycetes species that pose serious public health threats in immunocompromised patients, including those with...
- The National Institute of Allergy and Infectious Diseases awarded University of Tennessee Health Science Center $468,368 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate LGR4 expression and its role in HIV-associated atherosclerosis. The research examines molecular mechanisms linking controlled HIV infection to macrophage activation and accelerated atherosclerosis in people living with HIV on antiretroviral therapy. Using an experimental...
- The National Institute of Allergy and Infectious Diseases awarded East Carolina University $536,695 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on May 1, 2026. The award funds research into the roles of fibroblastic reticular cells (FRCs) in the establishment and maintenance of HIV-1 latently infected cells containing intact proviruses in people living with HIV under antiretroviral therapy. The project examines how FRCs, a type of secondary lymphoid organ stromal...
- The National Institute of Allergy and Infectious Diseases awarded the University of Tennessee $148,519 on June 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop adipose-derived stem cells as an in vitro model system for human cytomegalovirus latency. The recipient will establish conditions under which adipose-derived stem cells support latent HCMV infection and characterize the transcriptional program of latency using RNA sequencing, comparing...
- The National Institute of Allergy and Infectious Diseases awarded The Wistar Institute of Anatomy and Biology $707,928 on July 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research on epitope-engineered hematopoietic stem cells to enable CAR-T cell-mediated CD4 depletion as an HIV cure strategy. The project integrates genome editing with targeted cellular immunotherapy to establish an HIV-refractory immune system while eliminating persistent HIV-infected...
- The National Institute of Allergy and Infectious Diseases awarded the University of Tennessee $429,586 on August 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how viral neuraminidase remodels the epithelial glycocalyx to facilitate influenza A virus entry. The research addresses a mechanistic gap in understanding how the mucin-rich glycocalyx serves as a barrier to influenza infection. The project proposes that galectin-dependent crosslinking...